This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

One of the big themes we see emerging into 2025 is an expansion in Biotechnology and a bullish backdrop for certain biotechnology stocks.

The biotech sector is very defensive and non-cyclical due to the necessity of medications and healthcare treatment being largely independent of economic growth and market risk sentiment. Money is retu...

The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05...

The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on No...